Morbimortality of Pandemic Influenza A H1N1 Infection in Kidney Transplant Recipients Requiring Hospitalization: A Comparative Analysis With Nonimmunocompromised Patients

Camargo, Luís Fernando Aranha; Sandes‐Freitas, Tainá Veras de; Silva, Camila D. R.; Bittante, Carolina Devite; Ono, Gislaine; Corrêa, Luci; Silva, Moacyr; Bellei, Nancy; Goto, Janaína Midori; Medeiros, Eduardo Alexandrino; Gomes, Pollyane Sousa; Medina-Pestana, J.O.

doi:10.1097/tp.0b013e31823aa528

Cited by 12 publications

(11 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A taxa de letalidade encontrada em nosso estudo é se-melhante àquela observada em outros estudos publicados 19,26,28,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66 .…”

Section: Discussionunclassified

Relacionamento entre bases de dados para vigilância da pandemia de influenza A(H1N1)pdm09, Brasil, 2009-2010

Rossetto

Luna

2016

Cad. Saúde Pública

View full text Add to dashboard Cite

Resumo: O objetivo deste estudo foi o de descrever, com base no relacionamento entre os sistemas de informação SINAN (Sistema de Informação de Agravos de Notificação) e SIM (Sistema de Informações sobre Mortalidade), o perfil epidemiológico dos casos notificados de influenza por novo subtipo viral que evoluíram para óbito, durante a pandemia da doença. Foram utilizados dados secundários de ambos os sistemas referentes aos anos de 2009 e 2010. O relacionamento identificou 5.973 óbitos de casos notificados como influenza pandêmica. Destes, 2.170 (36,33%) haviam sido classificados no SINAN como confirmados para a enfermidade; 215 (3,6%), como infecção por outro agente infeccioso; e 3.340 (55,92%), como descartados. Após o relacionamento, alguns casos, que, no SINAN, foram encerrados com evolução para óbito por influenza (n = 658) ou óbito por outras causas (n = 847), não foram encontrados no SIM. O relacionamento entre os bancos de dados pode aprimorar o sistema de vigilância e o dimensionamento da morbimortalidade. Recomendamos o fortalecimento da vigilância da influenza no país com o uso do relacionamento entre os sistemas de informação do Ministério da Saúde.

show abstract

“…A taxa de letalidade encontrada em nosso estudo é se-melhante àquela observada em outros estudos publicados 19,26,28,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66 .…”

Section: Discussionunclassified

Relacionamento entre bases de dados para vigilância da pandemia de influenza A(H1N1)pdm09, Brasil, 2009-2010

Rossetto

Luna

2016

Cad. Saúde Pública

View full text Add to dashboard Cite

show abstract

“…130 Immunocompromised persons suffer from a more severe disease and are more likely to develop drugresistance mutations. 154,155 Numerous clinical studies especially on 2009 pandemic cases 156,157 and WHO or CDC recommendations 158,159 identify pregnancy as comorbidity factor for influenza and advise general vaccination of this risk population. Pregnant women are more susceptible for infection with influenza, develop a more severe disease associated with worse pregnancy outcomes, and show higher risk of ICU admission and increased mortality.…”

Section: At-risk Populationsmentioning

confidence: 99%

Human Influenza Virus Infections

Peteranderl

Herold

Schmoldt

2016

Semin Respir Crit Care Med

184

129

View full text Add to dashboard Cite

Seasonal and pandemic influenza are the two faces of respiratory infections caused by influenza viruses in humans. As seasonal influenza occurs on an annual basis, the circulating virus strains are closely monitored and a yearly updated vaccination is provided, especially to identified risk populations. Nonetheless, influenza virus infection may result in pneumonia and acute respiratory failure, frequently complicated by bacterial coinfection. Pandemics are, in contrary, unexpected rare events related to the emergence of a reassorted human-pathogenic influenza A virus (IAV) strains that often causes increased morbidity and spreads extremely rapidly in the immunologically naive human population, with huge clinical and economic impact. Accordingly, particular efforts are made to advance our knowledge on the disease biology and pathology and recent studies have brought new insights into IAV adaptation mechanisms to the human host, as well as into the key players in disease pathogenesis on the host side. Current antiviral strategies are only efficient at the early stages of the disease and are challenged by the genomic instability of the virus, highlighting the need for novel antiviral therapies targeting the pulmonary host response to improve viral clearance, reduce the risk of bacterial coinfection, and prevent or attenuate acute lung injury. This review article summarizes our current knowledge on the molecular basis of influenza infection and disease progression, the key players in pathogenesis driving severe disease and progression to lung failure, as well as available and envisioned prevention and treatment strategies against influenza virus infection.

show abstract

“…Solid organ transplant (SOT) recipients have a higher risk of influenza infection complications when compared to healthy individuals. This problem was evidenced in 2009 by the severity of pandemic influenza A/H1N1 (A(H1N1)pdm09) infection among SOT recipients . Kumar et al .…”

Section: Introductionmentioning

confidence: 99%

Antibody persistence 1 year after pandemic H1N1 2009 influenza vaccination and immunogenicity of subsequent seasonal influenza vaccine among adult organ transplant patients

et al. 2013

View full text Add to dashboard Cite

SummaryWe investigated the antibody persistence in solid organ transplant (SOT) recipients 1 year after immunization with two doses of monovalent AS03-adjuvanted influenza A(H1N1)pdm09 vaccine. We also assessed the boosting effect of the seasonal trivalent inactivated vaccine 2010 (TIV/10) that contained the influenza A (H1N1)pdm09 strain. A total of 49 SOT recipients and 11 healthy controls were included. After a blood sample was obtained to assess the persistent immunity, one dose of TIV/10 was administered and another blood sample was collected 1 month after vaccination. A(H1N1)pdm09 antibodies were measured using a haemagglutination inhibition assay. The percentage of SOT recipients with protective titres decreased between 1 month and 10-14 months after the monovalent influenza A(H1N1)pdm09 vaccination, from 79% (n = 38) to 47% (n = 23) (P = 0.02). The corresponding numbers for the control group were 100% and 63%, respectively (P = 0.008). After the TIV/10 boosting dose, the number of SOT recipients with protective titres increased from 47% (n = 23) to 71% (n = 35) (P = 0.2). All the controls reached a protective titre level. The median titre rise was significantly higher among controls when compared to SOT recipients (P = 0.0036). No rejection or adverse events were seen. The results show an obvious need for vaccine boosting doses in the SOT patients. (ClinicalTrials.gov number: NCT01256931).

show abstract

Morbimortality of Pandemic Influenza A H1N1 Infection in Kidney Transplant Recipients Requiring Hospitalization: A Comparative Analysis With Nonimmunocompromised Patients

Abstract: No significant differences in morbidity and mortality were observed comparing KT and non-KT patients infected with pandemic H1N1 influenza A virus.

Cited by 12 publications

References 15 publications

Relacionamento entre bases de dados para vigilância da pandemia de influenza A(H1N1)pdm09, Brasil, 2009-2010

Relacionamento entre bases de dados para vigilância da pandemia de influenza A(H1N1)pdm09, Brasil, 2009-2010

Human Influenza Virus Infections

Antibody persistence 1 year after pandemic H1N1 2009 influenza vaccination and immunogenicity of subsequent seasonal influenza vaccine among adult organ transplant patients

Contact Info

Product

Resources

About